RxDoctor Payments Data

Nicole Rush, OD

Optometrist · Bandon, ORNPI 1467400952

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $22,748 of the $23,496 with a category attached, or 96.8%. Johnson & Johnson Vision Care, Inc. accounts for 96.8% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2019 at $22,998 and has fallen 99.5% since, to $124 in 2025. Among optometrist clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$23,496in general payments, 2019–2025

Across 16 payments — averaging $1468.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson Vision Care, Inc.$23K
  • LKC Technologies, Inc.$260
  • Maculogix, Inc.$250
  • Alcon$116
  • Optos, Inc.$58
  • Dompe US, Inc.$29
  • plus $36 from 2 others

What the payments were for

  • Speaking & faculty fees$22,74897%
  • Food & beverage$7113%
  • Entertainment$380%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,496 in reported general payments places this provider in the 95th percentile of 684 optometrist providers in Oregon.

See all optometrist providers in Oregon

Medicare billing

Part B allowed, 2024
$152,495
Medicare patients
722
Services billed
2,109

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost15$9,090
Travoprost11$2,445
Brimonidine Tartrate16$2,111
Latanoprost138$1,842
Prednisolone Acetate18$1,071
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat25$578
Timolol Maleate26$407
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha21$330
ErythromycinErythromycin Base16$199

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan$13$9,09015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 684 optometrist providers in Oregon.

Other optometrist in Bandon

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →